Darren has forty three years in technical operations and 35 of those in biopharma. A mechanical engineer in his undergrad he went on to achieve his MBA from Duke University and progressed through multiple roles in biopharma field including synthetic molecule, biotech large molecule and now four years in the cell and gene therapy space. Darren did his formative years with great companies like GlaxoSmithKline, MedImmune and AstraZeneca plus numerous years consulting to dozens of companies in the industry both large and small.

A noted relationship manager, Darren has built innovative deals in capacity sharing, biosimilars and contract relationships as well as a general manager in CO facility, rebuilding the plant and building organization from ground up. Darren exited the large company manifest in 2019 to pursue entrepreneurial opportunities in cell and gene therapies. Clarus marks his fourth biotech startup, two which have reached successful exits and one he remains a board member.

His cell and gene experience includes CRISPR based deployments, medical device development in cancer ablation and now adjuvant technology. He was specifically chosen to build and teach the cell and gene curriculum at Univ of MD. His expertise is in deal and equity development to keep a comfortable fuel of finances under the wings of the team.